- Chemomab Therapeutics ( NASDAQ: CMMB ) stock rose ~17% on Tuesday after the company said that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application seeking to start a a phase 2 trial of CM-101 in adults with systemic sclerosis (SSc).
- The study, dubbed ABATE, is expected to enroll 45 patients with clinically active dermatologic, vascular or pulmonary SSc.
- "We are encouraged by the results of recent clinical studies of CM-101 in COVID patients with SSc-like acute lung injury and in NASH patients, which showed consistent trends in reducing multiple biomarkers associated with fibro-inflammatory disease," said Chemomab Chief Medical Officer Matt Frankel.
- SSc, also known as systemic sclerosis, is a disorder characterized by hardening and tightening of the skin. the condition may also cause issues in the blood vessels, organs and digestive tract.
For further details see:
Chemomab stock surges ~15% on FDA nod to start trial of CM-101 for systemic sclerosis